Despite aggressive treatment and an array of research, trying to find new approaches to tackle glioblastoma, it remains one of the deadliest primary cancers. Main culprits for resistance of glioblastoma to classical therapy are cancer stem cells (CSCs). Because tumour microenvironment is crucial for survival of GSCs and maintenance of GSC phenotype, those cells can be found in special areas near brain vasculature, known as perivascular GSC niches, which provide perfect environment for GSC survival. An important part of tumour microenvironment represent blood vessels that excrete molecules, such as chemokines and nitric oxide, and thereby promote growth of the tumour and lead to increased resistance of glioblastoma to therapy. Finding new targets to treat glioblastoma, which is nowadays still tackled with classical therapies, requires understanding the biology of GSC niches and interactions between GSCs and vascular cells.
In this work we investigated interactions between GSCs and vascular cells in perivascular niche and aimed to find out how chemotherapy affects those interactions as well as features of GSCs. We developed in vitro model of perivascular niche and tried to discover factors that contribute to invasion of GSCs into perivascular niche by using plerixafor, which inhibits SDF-1α/CXCR4 signalling pathway and L-NAME, inhibitor of NO synthase.
We discovered that endothelial as well as smooth muscle cells have a profound chemotactic effect on GSCs. We showed that signalling pathway SDF-1α/CXCR4 is crucial for chemotaxis of GSCs into periarteriolar niche, since CXCR4 inhibitor plerixafor significantly reduced invasion of GSCs in the niche. NO synthase inhibitor L-NAME on the other hand did not show any effect on the invasion of GSCs into perivascular niche. Chemotherapeutic temozolomide did not affect invasion of GSCs on their own, but it did inhibit invasion of GSCs into perivascular niche. Additionally, we discovered that inhibition of SDF-1α/CXCR4 pathway leads to GSC differentiation and that in presence of smooth muscle cells, GSCs start to acquire astrocyte-like phenotype.
The results of this work give new insight into understanding the resistance of glioblastoma to therapy and expose signalling pathway SDF-1α/CXCR4 as a possible target to inhibit GSC invasion into the perivascular niches. By using inhibitors of this pathway, such as plerixafor, we could lower the amount of GSCs in the perivascular niches and thereby sensitize GSCs to therapy.
|